TCGA-OR-A5JR-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- ALLOGRAFT_REJECTION+0.299
- OXIDATIVE_PHOSPHORYLATION+0.254
- MITOTIC_SPINDLE+0.225
- UV_RESPONSE_DN+0.210
- FATTY_ACID_METABOLISM+0.175
- COMPLEMENT+0.156
- IL6_JAK_STAT3_SIGNALING+0.150
- INTERFERON_GAMMA_RESPONSE+0.128
- BILE_ACID_METABOLISM+0.128
Top 10 suppressed
- MYC_TARGETS_V1-0.348
- MYC_TARGETS_V2-0.243
- PANCREAS_BETA_CELLS-0.239
- MYOGENESIS-0.224
- CHOLESTEROL_HOMEOSTASIS-0.212
- DNA_REPAIR-0.210
- WNT_BETA_CATENIN_SIGNALING-0.180
- G2M_CHECKPOINT-0.160
- UNFOLDED_PROTEIN_RESPONSE-0.158
- E2F_TARGETS-0.154
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475115 | — | — | 0.661 |
| 2 | TCGA-OR-A5JT-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.660 |
| 3 | TCGA-OR-A5JV-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.638 |
| 4 | SRR12475117 | — | — | 0.627 |
| 5 | TCGA-E9-A24A-01A-11R-A169-07 | — | B | 0.620 |
| 6 | SRR12475112 | — | — | 0.601 |
| 7 | SJEPD031233_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.599 |
| 8 | BS_H3FE3TH9 | pilocytic astrocytoma | — | 0.593 |
| 9 | SRR10900564 | — | — | 0.592 |
| 10 | ERR2598331 | fetal | fetal | 0.589 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.299 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.254 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.225 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.175 | Inavolisib | — uncovered |
| COMPLEMENT | 0.156 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.128 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.128 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.126 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.107 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.091 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.077 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.061 | Inavolisib | — uncovered |
| COAGULATION | 0.054 | Binimetinib | — uncovered |
| APOPTOSIS | 0.048 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.035 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.031 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.029 | Idelalisib | — uncovered |